What is the history of Insulinoma?

Insulinoma is a rare, usually benign neuroendocrine tumor of the pancreas that was first clinically described in 1927 by Dr. William Mayo. While historically difficult to diagnose, the evolution of biochemical testing and advanced medical imaging has transformed Insulinoma from a mysterious cause of "spontaneous hypoglycemia" into a highly treatable condition.

When was Insulinoma first discovered?

The medical understanding of Insulinoma began in 1927 when Dr. William Mayo performed the first successful surgical removal of an insulin-secreting tumor. Prior to this, patients suffering from the severe, unexplained hypoglycemia characteristic of Insulinoma were often misdiagnosed with epilepsy or psychiatric disorders, as the underlying endocrine dysfunction was not yet understood.

How has our understanding of Insulinoma evolved?

In the early 20th century, the discovery of insulin by Banting and Best provided the framework to identify Insulinoma as a functional tumor of the pancreatic beta cells. By 1935, Dr. Allen Whipple solidified the diagnostic criteria, known as "Whipple’s Triad," which remains a cornerstone of clinical practice today. This triad includes:

• Symptoms of hypoglycemia during fasting or exertion.


• A documented low blood glucose level during these symptomatic episodes.


• Immediate relief of symptoms following the administration of glucose.

What role does genetics play in Insulinoma?

While most cases of Insulinoma are sporadic, research has revealed that approximately 5-10% of cases are associated with Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary genetic syndrome. Modern genetic sequencing has allowed clinicians to better identify patients who may have underlying familial predispositions, shifting the focus toward personalized screening programs for at-risk families.

How have treatment milestones changed?

Historically, Insulinoma was treated via invasive "blind" pancreatic exploration. Today, the landscape is defined by precision:

• Development of highly sensitive assays to measure insulin and C-peptide levels.


• Advancements in endoscopic ultrasound (EUS) and PET/CT imaging to localize tumors with high accuracy.


• Minimally invasive laparoscopic surgical techniques that reduce recovery time significantly.

Next steps

• Consult an endocrinologist or pancreatic surgeon if you experience recurring symptoms of Whipple's Triad.


• Connect with the 15 Insulinoma community members on DiseaseMaps.org to share experiences.


• Request genetic counseling if there is a family history of neuroendocrine tumors.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Insulinoma.


• Orphanet: Rare pancreatic endocrine tumor.


• OMIM (Online Mendelian Inheritance in Man): Multiple Endocrine Neoplasia, Type I.


• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).